GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 12,019 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 12,019 shares of GeneDx stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $73.76, for a total transaction of $886,521.44. Following the sale, the chief financial officer now owns 32,932 shares of the company’s stock, valued at approximately $2,429,064.32. The trade was a 26.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $18,248.40.
• On Monday, September 9th, Kevin Feeley sold 895 shares of GeneDx stock. The shares were sold at an average price of $33.33, for a total value of $29,830.35.
• On Tuesday, September 3rd, Kevin Feeley sold 262 shares of GeneDx stock. The shares were sold at an average price of $31.71, for a total value of $8,308.02.

GeneDx Trading Up 2.2 %

NASDAQ:WGS opened at $80.46 on Tuesday. The firm has a market capitalization of $2.21 billion, a P/E ratio of -25.87 and a beta of 2.11. GeneDx Holdings Corp. has a 52 week low of $1.41 and a 52 week high of $89.11. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The company has a fifty day moving average of $60.46 and a 200 day moving average of $40.26.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.25. The firm had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company’s quarterly revenue was up 44.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.82) earnings per share. On average, research analysts predict that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Institutional Investors Weigh In On GeneDx

Institutional investors and hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new position in shares of GeneDx during the second quarter valued at approximately $34,000. nVerses Capital LLC bought a new position in GeneDx in the 2nd quarter worth $50,000. CWM LLC purchased a new stake in shares of GeneDx in the 3rd quarter worth about $89,000. Verition Fund Management LLC boosted its stake in shares of GeneDx by 12.9% during the 3rd quarter. Verition Fund Management LLC now owns 25,845 shares of the company’s stock valued at $1,097,000 after purchasing an additional 2,945 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of GeneDx by 36.1% during the second quarter. American Century Companies Inc. now owns 17,258 shares of the company’s stock valued at $451,000 after buying an additional 4,573 shares during the period. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Wall Street Analysts Forecast Growth

WGS has been the topic of a number of research reports. The Goldman Sachs Group raised their price objective on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. BTIG Research lifted their price target on shares of GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Wells Fargo & Company increased their target price on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. TD Cowen boosted their price target on shares of GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, Craig Hallum upped their price target on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.